Vita Life Sciences Ltd
ASX:VLS

Watchlist Manager
Vita Life Sciences Ltd Logo
Vita Life Sciences Ltd
ASX:VLS
Watchlist
Price: 2.48 AUD 0.81% Market Closed
Market Cap: 135.8m AUD
Section:
 

Relative Value

The Relative Value of one VLS stock under the Base Case scenario is 2.8 AUD. Compared to the current market price of 2.48 AUD, Vita Life Sciences Ltd is Undervalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VLS Relative Value
Base Case
2.8 AUD
Undervaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
23
vs Industry
64
Median 3Y
1.4
Median 5Y
1.4
Industry
2.6
More Details
14.9
P/E
P/E
Price to Earnings
14.9
vs History
6
vs Industry
35
Median 3Y
12.6
Median 5Y
12
Industry
21.6
More Details
13.7
P/OCF
P/OCF
Price to OCF
13.7
vs History
41
vs Industry
25
Median 3Y
13.3
Median 5Y
13
Industry
16.5
More Details
15.4
P/FCFE
P/FCFE
Price to FCFE
15.4
vs History
41
vs Industry
22
Median 3Y
14.6
Median 5Y
14.6
Industry
22.5
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
28
vs Industry
37
Median 3Y
2.4
Median 5Y
2.5
Industry
2.3
More Details
1.3
EV/S
EV/S
Enterprise Value to Sales
1.3
vs History
25
vs Industry
71
Median 3Y
1.1
Median 5Y
1.1
Industry
2.9
More Details
2.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.1
vs History
28
vs Industry
74
Median 3Y
1.9
Median 5Y
1.9
Industry
5.5
More Details
8.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.7
vs History
6
vs Industry
42
Median 3Y
7.1
Median 5Y
7
Industry
13
More Details
8.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8.7
vs History
6
vs Industry
44
Median 3Y
7.1
Median 5Y
7
Industry
16.6
More Details
11
EV/OCF
EV/OCF
Enterprise Value to OCF
11
vs History
41
vs Industry
32
Median 3Y
10.6
Median 5Y
10.6
Industry
15.8
More Details
12.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12.1
vs History
39
vs Industry
28
Median 3Y
11.3
Median 5Y
11.1
Industry
19.1
More Details
3.2
EV/IC
EV/IC
Enterprise Value to IC
3.2
vs History
31
vs Industry
29
Median 3Y
2.9
Median 5Y
2.9
Industry
1.9
More Details

Multiples Across Competitors

VLS Competitors Multiples
Vita Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Vita Life Sciences Ltd
ASX:VLS
138.7m AUD 1.6 14.9 8.7 8.7
US
Eli Lilly and Co
NYSE:LLY
996.3B USD 16.7 53.9 36.3 38.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
512.5B USD 5.6 20.5 16.7 21.6
CH
Roche Holding AG
SIX:ROG
255.3B CHF 4.1 27.1 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
209.7B GBP 4.8 29.9 108.3 158.5
CH
Novartis AG
SIX:NOVN
205.1B CHF 4.6 17.9 11.4 14.7
US
Merck & Co Inc
NYSE:MRK
250.5B USD 3.9 13.1 9.4 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.1
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
149B USD 2.4 15.1 7.7 10.5
P/E Multiple
Earnings Growth PEG
AU
Vita Life Sciences Ltd
ASX:VLS
Average P/E: 22.9
14.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.5
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.1
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBITDA: 399.7
8.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.7
9%
1.9
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
1%
7.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBIT: 1 711
8.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.6
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.7
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
8%
1.3

See Also

Summary
VLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
VLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VLS stock valuation using valuation multiples.
Wall Street Estimates
VLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.